MedElevator
Войти в исследования Clinical radiology · 2026
Clinical outcomes of genicular artery embolization for knee osteoarthritis in an indian observational cohort: the GENIE study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Damodharan K, Prasadaswamy V H, Majety S H, Mohandas P
Аннотация
AIMS: The GENIE Study (Genicular Artery Embolization: Indian Experience) evaluates real-world effectiveness and safety of GAE in an Indian cohort.
MATERIALS AND METHODS: This ambispective, single-centre observational study included patients who underwent GAE for symptomatic knee OA. Pain (Visual analogue score - VAS) and functional outcomes (Western Ontario and McMaster Universities Osteoarthritis Index - WOMAC) were assessed at baseline and follow-up timepoints up to 18 months. Safety outcomes included procedure-related adverse events, complications, repeat GAE, and conversion to total knee replacement (TKR).
RESULTS: A total of 122 patients were analysed. The majority of the patients (n=110, 90.2%) had advanced OA (mean Kellgren-Lawrence (KL) grade 3.8) making this study one of the very few to report outcomes of GAE in a large cohort of advanced OA patients. An average of 3.55 genicular vessels were embolized using permanent particulate embolic agents. VAS decreased from 8.79 ± 1.27 to 4.15 ± 2.54 at 18 months (mean reduction 4.64 ± 2.72; p<0.001). WOMAC improved from 76.64 ± 11.08 to 42.03 ± 18.93 (mean improvement 34.61 ± 17.55). Improvements were sustained through 18 months. Adverse events were mostly minor; TKR conversion remained low (1.6-4.1%). Minimal Clinically Important Difference (MCID) achievement was high at Week 2 (VAS 97.5%, WOMAC 94.3%) and remained substantial at 18 months (VAS 90.3%, WOMAC 76.7%), indicating sustained clinical benefit.
CONCLUSIONS: The GENIE Study demonstrates that GAE is a safe, effective, and durable minimally invasive treatment for knee OA in the Indian population. These findings reinforce its potential role within non-surgical OA management algorithms.
MATERIALS AND METHODS: This ambispective, single-centre observational study included patients who underwent GAE for symptomatic knee OA. Pain (Visual analogue score - VAS) and functional outcomes (Western Ontario and McMaster Universities Osteoarthritis Index - WOMAC) were assessed at baseline and follow-up timepoints up to 18 months. Safety outcomes included procedure-related adverse events, complications, repeat GAE, and conversion to total knee replacement (TKR).
RESULTS: A total of 122 patients were analysed. The majority of the patients (n=110, 90.2%) had advanced OA (mean Kellgren-Lawrence (KL) grade 3.8) making this study one of the very few to report outcomes of GAE in a large cohort of advanced OA patients. An average of 3.55 genicular vessels were embolized using permanent particulate embolic agents. VAS decreased from 8.79 ± 1.27 to 4.15 ± 2.54 at 18 months (mean reduction 4.64 ± 2.72; p<0.001). WOMAC improved from 76.64 ± 11.08 to 42.03 ± 18.93 (mean improvement 34.61 ± 17.55). Improvements were sustained through 18 months. Adverse events were mostly minor; TKR conversion remained low (1.6-4.1%). Minimal Clinically Important Difference (MCID) achievement was high at Week 2 (VAS 97.5%, WOMAC 94.3%) and remained substantial at 18 months (VAS 90.3%, WOMAC 76.7%), indicating sustained clinical benefit.
CONCLUSIONS: The GENIE Study demonstrates that GAE is a safe, effective, and durable minimally invasive treatment for knee OA in the Indian population. These findings reinforce its potential role within non-surgical OA management algorithms.